市場調查報告書
商品編碼
1541332
2024-2032 年按藥物類別、產品類型、應用、最終用戶和地區分類的促紅血球生成素藥物市場報告Erythropoietin Drugs Market Report by Drug Class, Product Type, Application, End-User, and Region 2024-2032 |
IMARC Group年全球促紅血球生成素藥物市場規模達110億美元。貧血和癌症盛行率不斷上升、慢性腎臟病治療應用的增加以及大眾對該藥物潛在影響的認知不斷提高,是推動市場發展的一些關鍵因素。
促紅血球生成素 (EPO) 藥物包括各種藥物,例如促紅血球生成素-α、紅血球生成素-BETA 和達貝泊汀-α,用於治療體內 EPO 缺乏症。它們是使用重組脫氧核糖核酸 (DNA) 技術合成製造的。它們刺激骨髓中紅血球(RBC)的產生並調節體內血紅素的濃度。它們有助於增強耐力、減少疲勞、增加新陳代謝和改善肌肉的癒合過程,同時保持體內紅血球的健康數量。它們用於治療個體之間的各種疾病,例如貧血、末期腎病、人類免疫缺陷病毒(HIV)和血液疾病。除此之外,運動員服用 EPO 藥物可以提高他們的表現和有氧能力,因為它們有助於增加肌肉的氧氣供應。
目前,由於個體中癌症和神經系統疾病,如自閉症、腦腫瘤、腦性麻痺、癲癇、注意力缺陷障礙(ADD)的盛行率不斷上升,群眾對EPO藥物的需求不斷增加,這是關鍵之一。除此之外,大眾對 EPO 藥物及其有效性的認知不斷提高,這提供了積極的市場前景。此外,世界各地群眾對外科手術介入的需求也在增加。再加上擴大使用 EPO 藥物來減少患者手術後的同種異體輸血,正在推動市場的成長。除此之外,全球範圍內慢性腎病(CKD)病例數量的不斷增加為行業投資者提供了利潤豐厚的成長機會。此外,EPO 藥物提供的各種益處,例如增加紅血球 (RBC) 和減輕疲勞,正在對市場產生積極影響。除此之外,世界各地促紅血球生成素生物相似藥的快速商業化正在推動市場的成長。再加上全球對生物相似藥而非參考藥的日益青睞,正在推動市場的成長。此外,研究機構擴大將 EPO 藥物作為新型治療劑用於眾多研究目的,這正在加強市場的成長。
The global erythropoietin drugs market size reached US$ 11.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 17.3 Billion by 2032, exhibiting a growth rate (CAGR) of 5% during 2024-2032. The growing prevalence of anemia and cancer, increasing application in treating chronic kidney disease, and rising awareness among the masses about the potential effects of the drug represent some of the key factors driving the market.
Erythropoietin (EPO) drugs comprise various drugs, such as epoetin-alfa, epoetin-beta, and darbepoetin-alfa, that are consumed to cure EPO deficiency in the body. They are manufactured synthetically using recombinant deoxyribonucleic acid (DNA) technology. They stimulate the production of red blood cells (RBCs) in bone marrow and regulate the concentration of hemoglobin in the body. They assist in enhancing endurance, reducing tiredness, increasing metabolism, and improving the healing process of muscles while maintaining a healthy amount of erythrocytes in the body. They are utilized to treat various diseases, such as anemia, end-stage renal disease, human immunodeficiency virus (HIV), and hematology, among individuals. Besides this, EPO drugs are consumed by athletes to enhance their performance and aerobic capacity, as they benefit in increasing the availability of oxygen to their muscles.
At present, the rising demand for EPO drugs among the masses due to the increasing prevalence of cancer and neurological diseases, such as autism, brain tumors, cerebral palsy, epilepsy, and attention deficit disorder (ADD), among individuals represents one of the key factors supporting the growth of the market. Besides this, the growing awareness among the masses about the EPO drugs and their effectiveness is offering a positive market outlook. Additionally, there is a rise in the need for surgical interventions among the masses around the world. This, coupled with the increasing utilization of EPO drugs to reduce allogeneic blood transfusions after surgical procedures in patients, is propelling the growth of the market. Apart from this, the rising number of chronic kidney disease (CKD) cases among individuals across the globe are offering lucrative growth opportunities to industry investors. Moreover, various benefits offered by EPO drugs, such as increasing red blood cells (RBCs) and reducing fatigue, are positively influencing the market. In addition to this, the rapid commercialization of erythropoietin biosimilars around the world is impelling the growth of the market. This, coupled with the increasing preference for biosimilar drugs rather than reference drugs across the globe, is contributing to the growth of the market. Furthermore, the rising utilization of EPO drugs as novel therapeutic agents in research institutes for numerous research purposes is strengthening the growth of the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global erythropoietin drugs market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on drug class, product type, application and end user.
Biologics
Biosimilars
The report has provided a detailed breakup and analysis of the erythropoietin drugs market based on the drug class. This includes biologics and biosimilars. According to the report, biologics represented the largest segment.
Epoetin-alfa
Epoetin-beta
Darbepoetin-alfa
Others
A detailed breakup and analysis of the erythropoietin drugs market based on the product type has also been provided in the report. This includes epoetin-alfa, epoetin-beta, darbepoetin-alfa, and others. According to the report, epoetin-alfa accounted for the largest market share.
Hematology
Kidney Disorder
Cancer
Others
A detailed breakup and analysis of the erythropoietin drugs market based on the application has also been provided in the report. This includes hematology, kidney disorder, cancer, and others. According to the report, kidney disorder accounted for the largest market share.
Hospitals
Homecare
Specialty Clinics
Others
A detailed breakup and analysis of the erythropoietin drugs market based on the end-user has also been provided in the report. This includes hospitals, homecare, specialty clinics, and others. According to the report, hospitals accounted for the largest market share.
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America (the United States and Canada) was the largest market for erythropoietin drugs. Some of the factors driving the North America erythropoietin drugs market included the increasing approvals of erythropoietin drugs, various incentives offered by governing agencies for research on chronic diseases, rising prevalence of cancer among individuals, etc.
The report has also provided a comprehensive analysis of the competitive landscape in the global erythropoietin drugs market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Amgen Inc., Biocon Limited, Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche AG, Intas Pharmaceuticals Ltd., Johnson & Johnson, LG Chem Ltd., Pfizer Inc., Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.